Browse the corpus

©2013 UpToDate ® Print Email Responses to approved antiviral therapies among treatment-naive patients with HBeAG-negative chronic hepatitis B Control/placebo groups from multiple studies, percent Standard IFN-α 5 MU daily or 10 MU three times per week for 6-12 months, percent Lamivudine 100 mg daily for 48-52 weeks, percent Adefovir 10 mg daily for 48 weeks, percent Entecavir 0.5 mg daily for 48 weeks, percent Telbivudine 600 mg daily for 52 weeks, percent Tenofovir 300 mg daily for 48 weeks, percent PegIFNα 180 mcg once weekly for 48 weeks, percent Peg IFNα 180 mcg once weekly + Lamivudine 100 mg daily for 48 weeks, percent Loss of serum HBV DNA* 0-20 60-70 60-73 51 90 88 93 63 87 Normalization of ALT 10-29 60-70 60-79 72 78 74 76 38 49 Histologic improvement 33 NA 60-66 64 70 67 72 48 38• Durability of response Control 10-20 <10 ~5 3 NA NA ~20 ~20 NA: not available. * Hybridization or branched chain DNA assays (lower limit of detection 20,000-200,000 international units/mL or 5-6 log copies/mL) in standard IFN-α studies and some lamivudine studies, and PCR assays (lower limit of detection approximately 50 international units/mL or 250 copies/mL) in other studies. • Post-treatment biopsies obtained at week 72. Reproduced with permission from: Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009; 50:661. Available online at file://publish.aasld.org/Pages/Default.aspx. Accessed September 8th 2009. Copyright © 2009 American Association for the Study of Liver Diseases.